Karo Pharma publishes prospectus relating to the rights issue
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.
The prospectus relating to the rights issue in Karo Pharma Aktiebolag (“Karo Pharma”) amounting to approximately MSEK 2,003 has today, on 30 September 2019, been approved and registered by the Swedish Financial Supervisory Authority. The prospectus is available on Karo Pharma’s website, www.karopharma.com, as well as on SEB’s website for prospectuses, www.sebgroup.com/prospectuses, and Swedbank’s website for prospectuses, www.swedbank.se/prospectus.
Application forms for subscription without subscription rights are available on Karo Pharma’s website and on each of SEB’s and Swedbank’s prospectus websites.
SEB Corporate Finance and Swedbank Corporate Finance are Joint Global Coordinators and White & Case is legal advisor to Karo Pharma in connection with the Rights Issue.
For further information, please contact:
Christoffer Lorenzen, CEO, +46 73 501 76 20, email@example.com
Mats-Olof Wallin, CFO, +46 76 002 60 10, firstname.lastname@example.org
About Karo Pharma
Karo Pharma is a pharmaceutical company specialised in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Karo Pharma Aktiebolag. Any invitation to those entitled to subscribe for shares in Karo Pharma Aktiebolag is made solely through the prospectus which Karo Pharma Aktiebolag makes public through this press release.
This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what is required pursuant to Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No subscription rights, paid subscribed shares (BTA) or new shares have or will be registered under the United States Securities Act of 1933 (the “Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is subject to, the registration requirements of the Securities Act. Neither is the offering aimed at individuals with residence in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland and Singapore or in any other jurisdiction where participation would require additional prospectus, registration or other arrangements aside of the Swedish law system.